4-Methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylic acid 4-propylcarbamoyl-phenyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-Methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylic acid 4-propylcarbamoyl-phenyl ester
• 英文别名: [4-(propylcarbamoyl)phenyl] 4-methyl-3-oxo-1,2,5,6-tetrahydrobenzo[c]quinolizine-8-carboxylate
• 化学式: C₂₅H₂₆N₂O₄
• 分子量: 418.492
• InChiKey: BQCNOPZLUIHOQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  75.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  一氧化碳 、 N-n-propyl-4-hydroxybenzoylamide 、 8-bromo-4-methyl-benzo[c]quinolizin-3-one 在 三乙胺 、 三苯基膦 、 palladium dichloride 作用下， 以 苯 为溶剂， 115.0~120.0 ℃ 、5.0 MPa 条件下， 反应 24.0h， 生成 4-Methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylic acid 4-propylcarbamoyl-phenyl ester
  参考文献：
  名称：

  Synthesis and activity of 8-substituted benzo[c]quinolizin-3-ones as dual inhibitors of human 5α-reductases 1 and 2

  摘要：

  Some potent dual inhibitors of 5alpha-reductases 1 and 2, based on the benzo[c]quinolizin-3-one structure and with IC50 values ranging between 93 and 166 nM for both isozymes, were found. The presence of the F atom on the ester moiety at the position 8 was crucial. This result can help in the design of other potent, dual inhibitors to be developed as drugs in the treatment of 5alpha-reductase related diseases. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.017

文献信息

• Synthesis and activity of 8-substituted benzo[c]quinolizin-3-ones as dual inhibitors of human 5α-reductases 1 and 2
  作者：Alessandro Ferrali、Gloria Menchi、Ernesto G. Occhiato、Giovanna Danza、Rosa Mancina、Mario Serio、Antonio Guarna

  DOI：10.1016/j.bmcl.2004.10.017

  日期：2005.1

  Some potent dual inhibitors of 5alpha-reductases 1 and 2, based on the benzo[c]quinolizin-3-one structure and with IC50 values ranging between 93 and 166 nM for both isozymes, were found. The presence of the F atom on the ester moiety at the position 8 was crucial. This result can help in the design of other potent, dual inhibitors to be developed as drugs in the treatment of 5alpha-reductase related diseases. (C) 2004 Elsevier Ltd. All rights reserved.